You are here: Industry Insights > Aravive

News List

Aravive Announces Dose Escalation of AVB-500 in Ovarian Cancer Treatment Trial americanpharmaceuticalreview
March 10, 2020
Aravive announced the independent Data Monitoring Committee (DMC) has reviewed the open-label data following the first 28-day treatment cycle for the three patients in each of the two 15 mg/kg dosing cohorts of the Phase 1b portion of ...
Aravive Receives IND Clearance for AVB-500 Trial for Clear Cell Renal Cell Carcinoma americanpharmaceuticalreview
January 17, 2020
Aravive announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for investigation of the company’s lead candidate, AVB-500, for the treatment of clear cell renal cell carcinoma (ccRCC
Aravive Announces Management Changes americanpharmaceuticalreview
January 13, 2020
Aravive has announced the appointment of Rekha Hemrajani as president, chief executive officer and director of the company. Jay Shepard, who last year announced plans to step down as Aravive’s CEO, will transition to the role of chairman of the board of d
Aravive Initiates Trial of AVB-500 in Patients with Kidney Fibrosis americanpharmaceuticalreview
December 23, 2019
Aravive announced the company has begun enrolling patients in the Phase 2a clinical trial of AVB-500 in patients with kidney fibrosis, specifically IgA Nephropathy (IgAN).